Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging
- PMID: 16982761
- DOI: 10.1158/0008-5472.CAN-06-1539
Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging
Abstract
The adenoviral E1A CR2 mutant dl922-947 has potent activity in ovarian cancer. We have used Renilla luciferase bioluminescence imaging to monitor viral E1A expression and replication and [18F]fluorothymidine positron emission tomography ([18F]FLT-PET) to quantify the activity of dl922-947 in vivo. We created dlCR2 Ren, with the same E1A CR2 deletion as dl922-947 and the luciferase gene from Renilla reniformis downstream of E1. Light emitted from s.c. and i.p. IGROV1 ovarian carcinoma xenografts was measured following treatment with dlCR2 Ren. Mice bearing s.c. IGROV1 xenografts were injected with 2.96 to 3.7 MBq of [18F]FLT 48 and 168 hours following i.t. injection of dl922-947 or control virus Ad LM-X. The presence of Renilla luciferase in dlCR2 Ren did not reduce in vitro nor in vivo potency compared with dl922-947. Light emission correlated closely with E1A expression in vitro and peaked 48 hours after dlCR2 Ren injection in both s.c. and i.p. IGROV1 xenografts. It diminished by 168 hours in s.c. tumors but persisted for at least 2 weeks in i.p. models. Normalized tumor [18F]FLT uptake at 60 minutes (NUV60), fractional retention, and area under radioactivity curve all decreased marginally 48 hours after dl922-947 treatment and significantly at 168 hours compared with controls. There was a close linear correlation between NUV60 and both tumor proliferation (Ki67 labeling index) and thymidine kinase 1 expression. Renilla luciferase bioluminescence and [18F]FLT-PET imaging are capable of quantifying the activity and effectiveness of E1A CR2-deleted adenoviral mutants in ovarian cancer.
Similar articles
-
Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin.Cancer Res. 2006 Jan 15;66(2):989-98. doi: 10.1158/0008-5472.CAN-05-2691. Cancer Res. 2006. PMID: 16424034
-
Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer.Oncogene. 2008 May 15;27(22):3081-90. doi: 10.1038/sj.onc.1210977. Epub 2007 Dec 10. Oncogene. 2008. PMID: 18071311 Free PMC article.
-
p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.Mol Cancer. 2010 Jul 3;9:175. doi: 10.1186/1476-4598-9-175. Mol Cancer. 2010. PMID: 20598155 Free PMC article.
-
Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo.Cancer Res. 2005 May 15;65(10):4202-10. doi: 10.1158/0008-5472.CAN-04-4008. Cancer Res. 2005. PMID: 15899811
-
Chapter five--The development of transcription-regulated adenoviral vectors with high cancer-selective imaging capabilities.Adv Cancer Res. 2012;115:115-46. doi: 10.1016/B978-0-12-398342-8.00005-7. Adv Cancer Res. 2012. PMID: 23021244 Review.
Cited by
-
A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth.Br J Cancer. 2013 Feb 5;108(2):342-50. doi: 10.1038/bjc.2012.576. Epub 2013 Jan 15. Br J Cancer. 2013. PMID: 23322205 Free PMC article.
-
Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents.Curr Protoc Pharmacol. 2009 Jun 1;45:14.12.1-14.12.26. Curr Protoc Pharmacol. 2009. PMID: 20634901 Free PMC article.
-
RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer.Mol Cancer Res. 2016 Jan;14(1):44-55. doi: 10.1158/1541-7786.MCR-15-0188-T. Epub 2015 Oct 9. Mol Cancer Res. 2016. PMID: 26452665 Free PMC article.
-
The future of imaging: developing the tools for monitoring response to therapy in oncology: the 2009 Sir James MacKenzie Davidson Memorial lecture.Br J Radiol. 2010 Oct;83(994):814-22. doi: 10.1259/bjr/77317821. Epub 2010 Aug 17. Br J Radiol. 2010. PMID: 20716650 Free PMC article.
-
Factors modulating expression of Renilla luciferase from control plasmids used in luciferase reporter gene assays.Anal Biochem. 2010 Jan 15;396(2):167-72. doi: 10.1016/j.ab.2009.09.043. Epub 2009 Sep 27. Anal Biochem. 2010. PMID: 19788887 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical